Publicly traded companies built around cryptocurrencies continue to draw investor attention, though their profiles can vary widely in size, approach, and risk. Looking at BMNR alongside SDEV highlights that range. One represents a multi-billion-dollar operator in the Bitcoin and Ethereum networks with a substantial treasury; the other is a smaller entity that has recently shifted focus to a specific protocol and the stablecoin space. This comparison matters for those assessing how different treasury strategies play out in terms of liquidity, volatility, and market behavior. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Bitmine Immersion Technologies, Inc. (BMNR) has positioned itself as a Bitcoin and Ethereum network company, becoming one of the larger corporate holders of Ethereum. It accumulates ETH for longer-term holding, with a significant portion staked to generate network rewards, while scaling back its own mining activities. Holdings have exceeded six million ETH, and the firm has noted combined crypto, cash, securities, and other strategic investments in the tens of billions of dollars.
Recently, BMNR completed its move to the New York Stock Exchange and increased its share repurchase program, alongside updates on record Ethereum holdings and staking growth. The stock has moved with notable swings, staying well below its 52-week peak even after a solid gain over the past three months. That pattern aligns with the broader improvement in digital asset sentiment and the stock’s historically high beta to market moves.
Stablecoin Development Corporation (SDEV), previously known as NovaBay Pharmaceuticals, Inc., now operates as an on-chain holding company centered on long-term involvement in protocol-aligned digital assets, with emphasis on the Sky protocol and the stablecoin sector. After the name change and ticker shift to NYSE American, the company has begun reporting staking rewards and adjustments to its SKY token positions.
Because the digital asset strategy is still relatively new, SDEV’s market presence remains in an early phase. Its market capitalization stays modest compared with larger peers, and share price action continues to reflect the uncertainties that come with a strategic shift. Recent trading has been driven mainly by investor evaluation of the transition, the rollout of the new mandate, and overall conditions in cryptocurrencies and stablecoins.
The clearest difference between BMNR and SDEV lies in scale and maturity. BMNR holds a market capitalization roughly 80 times larger than SDEV, supported by greater liquidity, a main NYSE listing, and a more established history in digital assets. SDEV, in contrast, is a smaller, recently reoriented company whose investment case is still developing in public markets.
On the business side, BMNR draws value chiefly from its large Ethereum treasury and staking activity, along with advisory and ecosystem services. SDEV maintains a more focused approach around protocol-specific assets in the Sky ecosystem and exposure to stablecoins. Growth factors follow suit: BMNR ties closely to ETH price changes and its accumulation plans, while SDEV depends on adoption of its chosen protocol and growth in the stablecoin area.
Risk profiles differ as well. Both face cryptocurrency volatility, yet BMNR’s higher beta and sizable treasury magnify price swings in reported results. SDEV carries added execution risk from its pivot and the lower liquidity common to small-cap names. Sector exposure overlaps but remains distinct: BMNR spans Bitcoin and Ethereum, while SDEV concentrates on one ecosystem and related stablecoin infrastructure.
In my own research process, I frequently review Tickeron’s AI Trading Bots to gauge how automated strategies are handling names like these. The platform offers a range of bots with different styles, risk settings, and performance metrics, which can provide additional perspective when evaluating volatility and trend consistency across crypto-treasury stocks. From what I see, this helps put current market behavior into a broader data-driven context without replacing individual analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SDEV as a result. In 57 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +16.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where SDEV advanced for three days, in 192 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 62 of 73 cases where SDEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The 10-day RSI Indicator for SDEV moved out of overbought territory on October 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 16 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SDEV turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 37 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SDEV moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SDEV crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SDEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SDEV broke above its upper Bollinger Band on October 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 6 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. SDEV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.430) is normal, around the industry mean (2.397). P/E Ratio (-0.173) is within average values for comparable stocks, (-3.450). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.319). Dividend Yield (0.000) settles around the average of (0.272) among similar stocks. P/S Ratio (16.639) is also within normal values, averaging (15.798).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SDEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
Industry InvestmentManagers